Consolidated sales of global products [IFRS]

(billion yen)

  FY2016 FY2017
XTANDI 252.1 294.3
  US 131.7 144.4
  Ex-US 120.4 149.9
    Japan 23.4 26.1
    Americas(Ex-US) 7.7 11.3
    EMEA* 85.3 106.7
    Asia and Oceania 4.0 5.8
Vesicare 116.1 102.3
  Japan 25.6 23.9
  Americas 53.1 41.3
  EMEA* 32.0 31.7
  Asia and Oceania 5.0 5.0
Betanis / Myrbetriq / BETMIGA 98.8 125.7
  Japan 25.9 29.5
  Americas 55.3 72.8
  EMEA* 14.1 18.3
  Asia and Oceania 3.5 5.2
Prograf 186.2 198.5
  Japan 48.8 48.3
  Americas 27.3 25.7
  EMEA* 70.1 78.7
  Asia and Oceania 37.3 42.5
  Exports to third parties 2.6 3.3
Harnal 47.7 49.6
Funguard/Mycamine 40.3 41.0

*Europe, the Middle East and Africa

 

Consolidated Sales of Other Products [IFRS]

Rx Sales in Japan

(billion yen)

  FY2016 FY2017
Micardis
Micombi
Micamlo
93.2 46.3
Celecox 47.6 48.3
Symbicort 39.3 39.5
Lipitor 23.2 19.6
Myslee 14.7 13.3
Bonoteo 13.8 13.3
Geninax 10.1 9.2
Suglat 9.5 11.6

 

RX Sales in Americas and Europe

(billion yen)

  FY2016 FY2017
Scan*
(Americas)
  71.5 73.6
Tarceva US 25.8 21.5
Ex-US 9.4 8.2

* Adenoscan + Lexiscan